Clinical Trials in Arizona

Showing 1601-1620 of 16,770 trials

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

NCT07463599

This trial will evaluate the safety, tolerability, and preliminary efficacy of tegavivint as monotherapy (single) and in combination with standard therapies in patients with metastatic colorectal carcinoma (mCRC).

Metastatic Colorectal Carcinoma (mCRC)Colorectal Cancer (CRC)Adenomatous Polyposis Coli (APC) Gene Mutation+1 more

HonorHealth Research Institute126 participantsStarted Feb 2026

Scottsdale, Arizona, United States

RECRUITINGPhase 331 miles

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT07104032

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).

Relapsed/Refractory Primary Central Nervous System Lymphoma

Ono Pharmaceutical Co., Ltd.132 participantsStarted Mar 2026

Scottsdale, Arizona, United States • New Haven, Connecticut, United States • New York, New York, United States +1 more locations

RECRUITINGPhase 331 miles

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

NCT06596252

The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.

Eosinophilic Esophagitis

Dr. Falk Pharma GmbH308 participantsStarted May 2021

Scottsdale, Arizona, United States • Little Rock, Arkansas, United States • La Jolla, California, United States +23 more locations

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Find Trials by Condition in Arizona

CARE: Cancer Risk Perception and Women of Color

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy

Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Cochlear Implantation in Children With Asymmetric Hearing Loss or Single-Sided Deafness Clinical Trial

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer